Troy Ignelzi
Director/Board Member at ABIVAX
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Marc M. P. de Garidel | M | 66 | 3 years | |
James Healy | M | 58 |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | 5 years |
Bernat Olle | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 years |
June Lee | M | 58 | 1 years | |
Abraham Ceesay | M | 46 |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | 3 years |
Philippe Pouletty | M | 65 | 11 years | |
Corinna Zur Bonsen-Thomas | M | - | 7 years | |
John Tucker | M | 61 | 7 years | |
David Bredt | M | - |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | 2 years |
Ben Shapiro | M | 84 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 years |
Jack Khattar | M | 62 | 8 years | |
Mason W. Freeman | M | 73 | 6 years | |
Didier Blondel | M | - | 7 years | |
Minnie Baylor-Henry | F | 76 | 6 years | |
Pierre Courteille | M | - | - | |
Klaus Veitinger | M | 62 | 7 years | |
Steve Paul | M | - |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | 2 years |
Frederick Hudson | M | 78 | 6 years | |
James Boland | M | 84 |
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | 9 years |
Carol Brosgart | M | 72 | 6 years | |
Raymond Kelleher | M | - |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | 1 years |
Sheldon Sloan | M | - | 1 years | |
Hema Keshava | F | - | 3 years | |
Jeremiah Faith | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
Patrick Malloy | M | - | 1 years | |
Michael Ferguson | M | - | 1 years | |
Regina Jehle | F | - | - | |
Ida Hatoum | F | - | 1 years | |
Neil Tiwari | M | 37 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
Terry-Ann Burrell | F | 47 |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | - |
Cheryl Gault | F | 44 |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | 1 years |
John Mohr | M | - | 7 years | |
Dan Littman | M | 71 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 years |
Kenya Honda | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 years |
Barton Finlay | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 years |
John LaMattina | M | 74 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 12 years |
Charles Sherwood | M | 76 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
Curt LaBelle | M | 53 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 1 years |
Jeffrey Tong | M | 48 |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | - |
Kinam Hong | M | - | - | |
Sanjay Mistry | M | - |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | 2 years |
Justin Thompson | M | - | 3 years | |
Daniel Couto | M | 52 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
Mike Hassman | M | - | 6 years | |
Martin Heidecker | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
Alexander Rudensky | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 years |
Reid Huber | M | 52 |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | - |
Didier Scherrer | M | - | - | |
Susan Dillon | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
Jose Matta | M | - |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Eric Elenko | M | 51 | 10 years | |
Atul Pande | M | 69 | 8 years | |
Jon Isaacsohn | M | - | - | |
William Meury | M | 56 | 1 years | |
Christopher Coughlin | M | 71 | 4 years | |
Tim Mayleben | M | 63 | 11 years | |
Jonathan Silverstein | M | 57 | 1 years | |
Michael Kalb | M | 53 | 1 years | |
Martin K. McCarthy | M | 65 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 years |
Kush Parmar | M | 42 | 4 years | |
Rick Bartram | M | 63 | 9 years | |
Abhay Gandhi | M | 59 | 2 years | |
Denice Torres | F | 64 | 4 years | |
Michael L. Babich | M | 47 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 years |
David Wheadon | M | 66 | 4 years | |
Heather Elizabeth Preston | M | 58 | 2 years | |
Patrick Enright | M | 62 | 3 years | |
Carol Karp | F | 71 | 1 years | |
Edmund Harrigan | M | 71 | 9 years | |
Daniel Janney | M | 58 | 9 years | |
Mia Kelley | F | - | 4 years | |
Jon W. McGarity | M | 82 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 1 years |
Jean-Jacques Bertrand | M | 85 | 9 years | |
Laurie Olson | F | 61 | 4 years | |
Robert Nelsen | M | 60 | 3 years | |
Joy Amundson | F | 69 | - | |
Louis Lange | M | 72 | 4 years | |
John Thero | M | 63 | 2 years | |
Jason Pitts | M | 38 | 2 years | |
Juliana Woda | M | - |
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | 1 years |
Mary Coelho | F | 62 | 1 years | |
Jonathan Rosin | M | - | 1 years | |
Ronald Marcus | M | 65 | 3 years | |
Charmaine Lykins | F | 54 | 2 years | |
Noah L. Rosenberg | M | 57 | 2 years | |
William Kane | M | 62 | 1 years | |
James E. Audia | M | 68 | 5 years | |
Ramesh Acharya | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
David Allison | M | 42 | 4 years | |
Stephen M. Muniz | M | - | - | |
August Troendle | M | 67 | 3 years | |
Maina Bhaman | M | 52 | 4 years | |
Joep Muijrers | M | 51 | 1 years | |
Steven J. Meyer | M | 67 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 years |
Christopher Viehbacher | M | 64 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
Jan L. Garfinkle | F | - | 5 years | |
Patrick P. Fourteau | M | 77 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 years |
Bharatt Chowrira | M | 59 | 2 years | |
Alexis Smith | F | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 85 | 85.86% |
France | 16 | 16.16% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Troy Ignelzi
- Personal Network